Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ERYtech Pharma, Teva sign agreement on Graspa
Graspa is a new enzyme formulation of L-asparaginase with a range of clinical uses compared to existing forms due to the enzymes entrapment and protection inside the homologous
Graspa is a new enzyme formulation of L-asparaginase with a range of clinical uses compared to existing forms due to the enzymes entrapment and protection inside the homologous
XGEVA, a RANK Ligand inhibitor approved by the US Food and Drug Administration (FDA), is indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases
The company has posted net loss of $9.77m, compared to $8.25m for the same period previous year. Gross profit was $8.39m, compared to $2.28m for the same period
RAPAFLO, a selective alpha-1 adrenergic receptor antagonist, maximizes target organ activity by binding with high affinity to the alpha (1A) receptors concentrated in the prostate. The double-blind, 12-week,
The company expects to recruit around 880 patients in 48 hospitals in 9 countries across three continents. The study, named as immunotherapy Multikine anti tumor treatments (IT-MATTERS), is
OHR/AVR118 an immunomodulator which modulates cellular pro-inflammatory chemokine and cykotine synthesis, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). The company said OHR/AVR118 has powerful chemoprotective effects which
PharmaNet is a provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device industries and provides capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence
CT-011, an experimental anti-PD-1 monoclonal antibody, has also achieved secondary endpoint of overall survival (OS) in the Phase II trial. Initial analysis demonstrated that 70% of the patients
Originally developed by Roxro Pharma, Sprix is a prescription intranasal formulation of the analgesic ketorolac, a non-steroidal anti-inflammatory drug (NSAID). The spray is packaged in boxes that comprises
GBI is a cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines. GBI also offers process development services from proof of concept and preclinical through phase II